The Motley Fool

2 under-the-radar stocks on my watch list this September

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Over the past 12 months, shares in Ekf Diagnostics (LSE: EKF) have chugged higher by 50% as investors have regained trust in the company following a turbulent few years. 

Indeed, after hitting a high of 38p per share at the beginning of 2014, shares in Ekf slumped to a low of 8.8p at the beginning of 2016 as losses rose fivefold. 

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

But it now looks as if the firm is back on track. According to its half-year report published today, the medical diagnostics and testing company saw revenues expand 22.8% for the six months to the end of June. Gross profit for the period rose 40.6% to £11.8m. Adjusted earnings before interest, tax, depreciation, and amortisation more than doubled from £2m to £4.6m and the company moved into a net cash position of £4.4m, up from a net debt balance of £4.3m at the end of the same period last year.  

Simplify and streamline

These figures reflect management’s efforts to simplify and streamline the business following its previous problems. The number of manufacturing facilities has been reduced from 12 to seven and a rise in orders has helped accelerate profit margin expansion. For the full year, City analysts have pencilled in earnings per share of 0.9p on a pre-tax profit of £3.8m and revenues of £41.6m. Based on these estimates the shares are trading at a forward P/E of 29.4. 

Some investors might be discouraged by Ekf’s valuation, but I believe that the shares deserve a place on my watchlist because of the company’s strong growth, rapidly growing cash balance and plans to return cash to investors. Management has recently announced plans to buy back up to 15% of the company’s outstanding shares to reward shareholders and celebrate Ekf’s return to profitability. 


Another British diagnostic company I’m keeping an eye on this month is Oxford Instruments (LSE: OXIG). Oxford specialises in nanotechnology tools and services that enable materials characterisation and sample manipulation at the nano scale. 

Oxford grew rapidly until 2015 when growth went into reverse and the shares lost around two-thirds of their value in a year. Nonetheless, growth has now returned and investors are starting to trust the company again. For the fiscal year ending 31 March 2018 City analysts are expecting the company to report earnings per share of 53.6p, up 12% year-on-year on a pre-tax profit of £40.5m. Earnings growth of 9% is projected for the following year. 

Unfortunately, like Ekf, Oxford also trades at a high valuation, but I believe this is warranted as management’s decision to sell its industrial analysis unit would leave the group more focused on the higher-margin nanotechnology and services, and this specialist focus deserves a premium valuation. 

The shares currently trade at a forward P/E of 21. I believe as the market wakes up to Oxford’s more focused business, which should be able to produce higher profit margins, the shares should re-rate to an even higher valuation. For example, shares in specialist engineering group Renishaw trade at a forward P/E of 32. 

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has recommended Renishaw. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.